对照组

LT后新发NAFLD组

P值

(N = 73)

(N = 40)

随访时间

3.4 ± 1.8

3.5 ± 1.6

0.692

年龄

54.5 ± 10.8

51.9 ± 7.5

0.143

性别(男)

76.70%

82.50%

0.472

BMI

23.4 ± 2.4

26.5 ± 4.0

<0.001

腰围

87.3 ± 9.0

95.6 ± 11.2

<0.001

CAP

198.8 ± 43.0

260.6 ± 67.7

<0.001

LSM

6.5 ± 3.1

9.1 ± 6.7

0.025

白蛋白

43.6 ± 6.65884

42.7 ± 5.6

0.512

GGT

33.6 ± 54.3

34.3 ± 22.5

0.933

ALP

87.6 ± 38.9

78.7 ± 19.1

0.104

ALT

20.5 ± 11.0

23.2 ± 8.9

0.186

AST

23.6 ± 9.2

24.4 ± 7.8

0.628

总胆红素

22.7 ± 11.2

21.3 ± 10.1

0.669

甘油三酯

1.1 ± 0.5

1.5 ± 0.6

0.001

总胆固醇

4.6 ± 0.9

4.9 ± 0.8

0.073

HDL

1.6 ± 0.4

1.4 ± 0.3

0.016

LDL

2.7 ± 0.8

2.4 ± 0.6

0.11

淋巴细胞计数

1.4 ± 0.7

1.5 ± 0.7

0.81

血小板

182.4 ± 68.9

165.9 ± 54.1

0.192

肌酐

101.2 ± 28.4

99.0 ± 16.9

0.653

血糖

5.8 ± 1.4

5.9 ± 1.4

0.779

尿酸

350.5 ± 102.0

372.3 ± 92.1

0.265

高血压

39.70%

47.50%

0.424

糖尿病

30.10%

25.00%

0.562

代谢综合征

21.90%

42.50%

0.021

供肝脂肪变性

28.80%

35.00%

0.375

原发性肝病

0.676

肝癌

45.2%

57.5%

慢性乙肝

24.7%

15.0%

酒精性肝硬化

5.5%

5.0%

肝衰竭

4.1%

10.0%

药物性肝损害

1.4%

2.5%

原发性胆汁性肝硬化

2.7%

0

自身免疫性肝硬化

4.1%

0

肝豆状核变性

1.4%

0

其他

9.6%

10.0%

原发性硬化性胆管炎

1.4%

0

免疫抑制剂

类固醇

16.4%

12.5%

0.575

MMF

43.8%

40.0%

0.693

CNI

89.0%

82.5%

0.327

m-TOR

24.7%

27.5%

0.741